In patients with endometrial cancer (N=94), endometrial polyps (N=28), endometrial hyperplasia (N=25), and healthy women (N=77), the serum contents of MMP-2, MMP-7, MMP-9, TIMP-1, and TIMP-2 were measured by ELISA. Both carcinoma and benign neoplasms were accompanied by significant elevation of MMP-7 and TIMP-2 in blood serum. The greatest elevation (in comparison with the control) was observed for MMP-7, although serum concentration of this marker was practically identical in patients with carcinoma and benign tumors. In contrast, the levels of MMP-2 and TIMP-1 were lower in cancer patients in comparison with the control; in these patients, the levels of MMP-9 and TIMP-1 were also lower than the corresponding levels in patients with polyps and endometrial hyperplasia. There were no significant correlations between the levels of examined markers with tumor metastasizing, its histological structure, and differentiation degree of endometrial cancer. No differences were observed between examined serological markers in patients with polyps and endometrial hyperplasia of various severities. The examined MMPs and TIMPs cannot be advanced as potential diagnostic markers of endometrial cancer, but they can be used to monitor and prognosticate the disease and to assess effectiveness of the targeted therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gershtein ES, Kushlinskii NE. Clinical Prospects of Tumor-Associated Proteases and Their Tissue Inhibitors Investigation in Oncologic Patients. Vestn. Ross. Akad. Med. Nauk. 2013;(5):16-27. Russian.
Adamiak A, Postawski K, Semczuk A, Rechberger T, Jakowicki JA. Prognostic value of serum MMP-2 level in uterine cancer affected women. Ginekol. Pol. 2000;71(9):1198-1201.
Erdemoglu E, Güney M, Karahan N, Mungan T. Immunohistochemical expression of MMP-2, MMP-9 and COX-2 in Stage IA malignant polyps of the endometrium. Eur. J. Gynaecol. Oncol. 2008;29(5):444-449.
Graesslin O, Cortez A, Fauvet R, Lorenzato M, Birembaut P, Daraï E. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann. Oncol. 2006;17(4):637-645.
Grybos A, Bar J. The relationships between the immunoexpression of KAI1, MMP-2, MMP-9 and steroid receptors expression in endometrial cancer. Folia Histochem. Cytobiol. 2014;52(3):187-194.
Honkavuori M, Talvensaari-Mattila A, Puistola U, Turpeenniemi-Hujanen T, Santala M. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma. Anticancer Res. 2008;28(5A):2715-2719.
Honkavuori-Toivola M, Santala M, Soini Y, Turpeenniemi-Hujanen T, Talvensaari-Mattila A. Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma. Dis. Markers. 2013;35(4):261-266.
Määttä M, Soini Y, Liakka A, Autio-Harmainen H. Localization of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Enhanced expression by endometrial adenocarcinomas is associated with low differentiation. Am. J. Clin. Pathol. 2000;114(3):402-411.
Moser PL, Hefler L, Tempfer C, Neunteufel W, Kieback DG, Gitsch G. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer. Anticancer Res. 1999;19(3B):2365-2367.
Pilka R, Norata GD, Domanski H, Andersson C, Hansson S, Eriksson P, Casslén B. Matrix metalloproteinase-26 (matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer. Gynecol. Oncol. 2004;94(3):661-670.
Puljiz M, Puljiz Z, Vucemilo T, Ramić S, Knezević F, Culo B, Alvir I, Tomica D, Danolić D. Prognostic significance of matrix metalloproteinases 2 and 9 in endometrial cancer. Coll. Antropol. 2012;36(4):1367-1372.
Shaco-Levy R, Sharabi S, Piura B, Sion-Vardy N. MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium. Acta Obstet. Gynecol. Scand. 2008;7(8):868-874.
Ueno H, Yamashita K, Azumano I, Inoue M, Okada Y. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int. J. Cancer. 1999;84(5):470-477.
Weigel MT, Krämer J, Schem C, Wenners A, Alkatout I, Jonat W, Maass N, Mundhenke C. Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012;160(1):74-78.
Yuan Y, Shen N, Yang SY, Zhao L, Guan YM. Extracellular matrix metalloproteinase inducer and matrix metalloproteinase-2 overexpression is associated with loss of hormone receptor expression and poor prognosis in endometrial cancer. Oncol. Lett. 2015;10(1):342-348.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 165, No. 1, pp. 88-93, January, 2018
Rights and permissions
About this article
Cite this article
Gershtein, E.S., Mushtenko, S.V., Ermilova, V.D. et al. Matrix Metalloproteinases and Their Tissue Inhibitors in Blood Serum of Patients with Endometrial Cancer: Clinical and Morphological Correlations. Bull Exp Biol Med 165, 75–79 (2018). https://doi.org/10.1007/s10517-018-4103-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-018-4103-0